Navigation Links
Telik Announces Preclinical Data Demonstrating Anti-Cancer Activity of Dual Inhibitors of Aurora Kinase and VEGFR2
Date:10/25/2007

PALO ALTO, Calif., Oct. 25 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) reported positive preclinical data from its ongoing program to develop novel small molecule inhibitors of validated cancer targets including aurora kinases and VEGFR2. The data were presented today at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics in San Francisco.

Aurora kinases are enzymes that play a key role in mitosis, or cell division. They are over-expressed in many human cancers, including breast, colon, pancreas, prostate and thyroid cancer, and are associated with carcinogenesis. Several aurora kinase inhibitors are currently under clinical evaluation for the treatment of cancer.

The VEGF receptor 2 (VEGFR2/KDR/Flt-1), a clinically validated target, plays a pivotal role in controlling angiogenesis and metastasis. A single agent that targets both aurora kinases and VEGFR2 may offer advantages of simultaneously attacking the ability of cancer cells to grow and divide while starving existing tumors of needed blood supply.

Telik scientists have identified a class of selective small molecule inhibitors of aurora kinase A and B and VEGFR2. Treatment of human colorectal cancer cells with two of these inhibitors, A60 and EA19, prevented cell division, ultimately leading to cancer cell apoptosis (programmed cell death). These same compounds are potent inhibitors of VEGF-dependent human endothelial cell proliferation. These agents demonstrated significant inhibition of tumor growth in a standard xenograft model of human colorectal cancer.

"These data support the continued development of aurora kinase and VEGFR2 inhibitors," said James G. Keck, Ph.D., vice president, biology research. "We are actively pursuing studies which, if successful, could support the filing of an investigational new drug application."

Telik, Inc. of Palo Alto, CA is a biopharmaceutical company focused on discovering, developing and commercializing novel small molecule drugs to treat serious diseases. The company's most advanced drug development candidates are TELCYTA(R), a tumor-activated small molecule product candidate in clinical development for the treatment of advanced ovarian cancer and non-small cell lung cancer; and TELINTRA(R), which is in clinical development for the treatment of myelodysplastic syndrome. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP(TM), which enables the rapid and efficient discovery of small molecule drug candidates. Additional information is available at http://www.telik.com

TELIK, the Telik logo, TELCYTA, TELINTRA and TRAP are trademarks or registered trademarks of Telik, Inc.


'/>"/>
SOURCE Telik, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Telik Reports Positive Data Demonstrating Synergy in Combination and Highly Statistically Significant Effect of Telcyta as Maintenance Therapy in First-Line Non-Small Cell Lung Cancer
2. Telik Announces Telcyta Clinical and Preclinical Presentations at AACR Meeting
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Sygnis Pharma AG announces date for presentation of clinical results
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... Divoti USA will engrave and process all non-coated ... latest FDA requirements, which stipulates new criteria regarding medical device manufacture ... Medical ID jewelry such as Medical ID Bracelets, can rest assured ... of the new FDA requirements . ... Divoti offers this dark mark fiber laser engraving process ...
(Date:10/11/2017)... 2017  BioPharmX Corporation (NYSE MKT: BPMX) researchers were ... innovative way to use nonlinear optical imaging to confirm ... drugs. A ... show how researchers from BioPharmX and the Wellman Center ... a suite of imaging techniques in what is called ...
(Date:10/11/2017)...  True Health, a leader in integrated diagnostics ... National Breast Cancer Awareness month to educate doctors ... Research recently published in ... than 10 million American women are at significant ... BRCA2 and have not had testing. These mutations can ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... As health professionals work to improve ... engagement.” The patient is doing more than filling out a survey; in many cases ... an increasing emphasis in health care and research on the importance of active engagement ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... ‘17, and Jennifer Huggins, PharmD ’17, along with clinical associate professor Janice ... of cardiovascular diseases during the 15th Annual Women’s Health Conference. The SIU ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Ellevate Network, the ... business to advocate for action towards gender equality at their inaugural Summit in New ... the globe, and reached a social audience of over 3 million. To watch the ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the ... danger possible to save lost souls in the Philippines. “The Journey: From the Mountains ... a dedicated teacher of the Bible. She has taught all ages and currently teaches ...
(Date:10/12/2017)... ... 12, 2017 , ... The company has developed a suite ... regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been developed ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, ...
Breaking Medicine News(10 mins):